McKesson strikes $2.25B deal to snap up Precision Medicine Group

The healthcare conglomerate, which ranks eighth on the Fortune 500 list, is set to envelop privately held Precision Medicine Group into its oncology branch as part of an ongoing effort to grow its high-margin cancer and biopharma businesses.